(Q34647400)

3 August 2017

1 reference

title

Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease (English)

1 reference

25492998

non-alcoholic fatty liver

3 August 2017

main subject

1 reference

metabolic dysfunction–associated steatotic liver disease

inferred from title

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Claudio Zulli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Marcello Dallio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Mario Masarone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Carmelina Loguercio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Ilario de Sio

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Anna Del Prete

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

1 December 2014

1 reference

25492998

World Journal of Gastroenterology

3 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

16841-16857

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

Controversies in the Diagnosis and Management of NAFLD and NASH.

11 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Thyroid hormone analogues and derivatives: Actions in fatty liver

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Dietary habits and behaviors associated with nonalcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Microbiota and nonalcoholic steatohepatitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Diets and nonalcoholic fatty liver disease: the good and the bad.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Bile acid receptors in non-alcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The role of endocannabinoids system in fatty liver disease and therapeutic potentials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Cannabinoid signaling and liver therapeutics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The role of lifestyle change in the prevention and treatment of NAFLD.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Treatment of NASH with ursodeoxycholic acid: pro.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Herbal products: benefits, limits, and applications in chronic liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Review article: fructose in non-alcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Is there any progress in the treatment of non-alcoholic fatty liver disease?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The potential for caspases in drug discovery

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Endocannabinoids and their role in fatty liver disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Adenosine: tipping the balance towards hepatic steatosis and fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Non-alcoholic fatty liver disease from pathogenesis to management: an update

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Current and emerging therapies in nonalcoholic fatty liver disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

FXR signaling in metabolic disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Biology of incretins: GLP-1 and GIP

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Transcriptional coregulators in the control of energy homeostasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The evolving role of leptin and adiponectin in chronic liver diseases

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Hepatic effects of dietary weight loss in morbidly obese subjects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Epidemiology of non-alcoholic fatty liver disease.

7 July 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Betaine and nonalcoholic steatohepatitis: back to the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Adenosine signaling contributes to ethanol-induced fatty liver in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I45.16841

Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

How different is the dietary pattern in non-alcoholic steatohepatitis patients?

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258554

The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study

9 December 2018

1 reference

12 December 2020

[Hepatoprotective properties of silymarin]

1 reference

12 December 2020

Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial

1 reference

12 December 2020

Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake

1 reference

12 December 2020

Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH)

1 reference

12 December 2020

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

1 reference

12 December 2020

Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study

1 reference

12 December 2020

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

1 reference

12 December 2020

Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance

1 reference

12 December 2020

Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease

1 reference

12 December 2020

Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study

1 reference

12 December 2020

Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease

1 reference

12 December 2020

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet

1 reference

12 December 2020

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

1 reference

12 December 2020

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

1 reference

12 December 2020

Dietary habits and nutrient intake in non-alcoholic steatohepatitis

1 reference

12 December 2020

10.3748/WJG.V20.I45.16841

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

release_cnpymcnmejhu3m4vcpsl5nyd5y

11 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cnpymcnmejhu3m4vcpsl5nyd5y

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

25492998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25492998%20AND%20SRC:MED&resulttype=core&format=json